Caffeine Preferentially Protects Against Oxygen-Induced Retinopathy

Shuya Zhang,Rong Zhou,Bo Li,Haiyan Li,Cun Wang,Yanyan Wang,Xuejiao Gu,Dingjuan Zhong,Lingyun Tang,Yuanyuan Ge,Yuqing Huo,Jing Lin,Xiao-Ling Liu,Jiang-Fan Chen
DOI: https://doi.org/10.1096/fj.201601285r
2017-01-01
Abstract:Retinopathy of prematurity (ROP) is the leading cause of childhood blindness, but current anti-VEGF therapy is concerned with delayed retinal vasculature, eye, and brain development of preterm infants. The clinical observation of reduced ROP severity in premature infants after caffeine treatment for apnea suggests that caffeine may protect against ROP. Here, we demonstrate that caffeine did not interfere with normal retinal vascularization development but selectively protected against oxygen-induced retinopathy (OIR) in mice. Moreover, caffeine attenuated not only hypoxia-induced pathologic angiogenesis, but also hyperoxia-induced vaso-obliteration, which suggests a novel protection window by caffeine. At the hyperoxic phase, caffeine reduced oxygen-induced neural apoptosis by adenosine A(2A) receptor (A(2A)R)-dependent mechanism, as revealed by combined caffeine and A(2A)R-knockout treatment. At the hypoxic phase, caffeine reduced microglial activation and enhanced tip cell formation by A(2A)R-dependent and -independent mechanisms, as combined caffeine and A(2A)R knockout produced additive and nearly full protection against OIR. Together with clinical use of caffeine in neonates, our demonstration of the selective protection against OIR, effective therapeutic window, adenosine receptor mechanisms, and neuroglial involvement provide the direct evidence of the novel effects of caffeine therapy in the prevention and treatment of ROP.
What problem does this paper attempt to address?